Analysts Set Immuneering Co. (NASDAQ:IMRX) Price Target at $12.60

Shares of Immuneering Co. (NASDAQ:IMRX) have earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $12.80.

A number of research analysts have recently commented on IMRX shares. Chardan Capital reiterated a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Immuneering in a research report on Thursday, November 14th.

Institutional Trading of Immuneering

Several hedge funds and other institutional investors have recently bought and sold shares of IMRX. Vanguard Group Inc. boosted its stake in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after buying an additional 129,851 shares during the period. Marshall Wace LLP bought a new stake in shares of Immuneering in the 2nd quarter worth about $492,000. Renaissance Technologies LLC purchased a new position in shares of Immuneering during the 2nd quarter worth about $447,000. Acadian Asset Management LLC purchased a new position in shares of Immuneering during the 2nd quarter worth about $67,000. Finally, HighTower Advisors LLC grew its holdings in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares during the last quarter. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Trading Down 0.5 %

Shares of IMRX stock opened at $2.10 on Wednesday. The stock has a market capitalization of $65.21 million, a price-to-earnings ratio of -1.07 and a beta of -0.40. Immuneering has a 12-month low of $1.00 and a 12-month high of $8.89. The stock’s 50-day moving average price is $2.22 and its 200-day moving average price is $1.63.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.